LEVIN MARK J 4
4 · Fulcrum Therapeutics, Inc. · Filed Jul 22, 2019
Insider Transaction Report
Form 4
LEVIN MARK J
Director10% Owner
Transactions
- Conversion
Common Stock
2019-07-22+5,595,238→ 5,880,952 total(indirect: By fund) - Purchase
Common Stock
2019-07-22$16.00/sh+81,250$1,300,000→ 5,962,202 total(indirect: By fund) - Conversion
Series A Preferred Stock
2019-07-22−39,166,667→ 0 total(indirect: By fund)→ Common Stock (5,595,238 underlying)
Footnotes (2)
- [F1]On July 22, 2019, the Series A Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III LP"). The general partner of TRV GP III LP is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III LP, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.